ArticleJAMA network open2026
Enrollment in Integrated Special Needs Plans Among Dually Eligible Beneficiaries With Serious Mental Illness.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Importance: Fragmentation between Medicare and Medicaid exacerbates access barriers, delays in care, and poor financial and health outcomes among the more than 4 million dually eligible beneficiaries with serious mental illness (SMI). Integrated dual-eligible special needs plans (D-SNPs), including highly integrated D-SNPs (HIDE-SNPs) and fully integrated D-SNPs (FIDE-SNPs), are Medicare Advantage (MA) plans that financially integrate Medicare and Medicaid benefits and may address the significant behavioral health, medical, and long-term service and support needs in this population. Objective: To examine enrollment and disenrollment in integrated D-SNPs relative to other Medicare options among dually eligible beneficiaries with SMI from 2019 to 2022. Design, Setting, and Participants: This retrospective cohort study of a 20% sample of dually eligible beneficiaries with SMI and full Medicaid benefits used Medicare administrative data from 2019 to 2022, including traditional Medicare fee-for-service claims data and MA encounter data. Data were analyzed from September 1, 2025, to April 3, 2026. Main Outcomes and Measures: Enrollment and disenrollment in integrated D-SNPs relative to other Medicare options (traditional Medicare, standard MA, and coordination-only D-SNPs) from 2019 to 2022, as well as enrollee demographic, clinical, and geographic characteristics. Results: This study included 719 542 dually eligible beneficiaries with a diagnosis of SMI (mean [SD] age, 64 [16] years; 459 555 women [63.9%]). The proportion of dually eligible beneficiaries with SMI enrolled in integrated HIDE-SNPs or FIDE-SNPs increased from 2.4% in 2019 to 17.2% in 2022, with a corresponding decrease in traditional Medicare enrollment from 58.6% to 42.6% in the same period. Cardiovascular disease (CVD), which is associated with excess mortality in SMI, was prevalent: 32.1% of beneficiaries had 3 CVD risk factors. More than half of states had no integrated D-SNP offerings, including states ranked highest for prevalence of comorbid CVD among dually eligible beneficiaries with SMI. A total of 10.3% of dually eligible beneficiaries with SMI enrolled in HIDE-SNPs and 6.1% of beneficiaries enrolled in FIDE-SNPs in 2021 disenrolled by 2022, relative to 20.9% disenrollment from standard MA. Conclusions and Relevance: This retrospective cohort study of dually eligible beneficiaries with SMI found increases in integrated D-SNP enrollment and limited disenrollment, which may suggest a high level of enrollee satisfaction. More research is needed to assess the association of integrated D-SNP enrollment with health outcomes among dually eligible beneficiaries with SMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.